OOIR: Observatory of International Research

Papers

(The median citation count of Annals of Hepatology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	407
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	114
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	73
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	61
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	59
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	48
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	44
P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	43
Energy metabolism: An emerging therapeutic frontier in liver fibrosis	36
Comment on “burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990–2021: Results from the global burden of disease study, 2021”	33
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	33
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	33
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	32
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	30
Acute Liver Failure due to Hepatitis A Virus: A Report of Two Cases	28
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	28
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	28
Neutrophil/lymphocyte index as a prognostic predictor in patients with primary biliary cholangitis	27
Skeletal muscle as a source of IGFBP-2 in a murine model of metabolic dysfunction associated with steatotic liver disease.	27
Characterization and determination of prevalence in autoimmune liver diseases in a tertiary center.	27
Reply to: “correspondence about “Efficacy and safety of basiliximab”	26
Kasabach-Merritt syndrome in an adult treated by embolization prior to liver transplantation: a case report.	26
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	26
“THE EFFECT OF GROWTH DIFFERENTIATION FACTOR 11 (GDF11) ON THE RESPONSE OF TUMOR-ASSOCIATED MACROPHAGES IN HEPATOCELLULAR CARCINOMA DERIVED CELLS”	24
A thorny matter: Spur cell anemia	23

Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	22
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	22
Examining genetic associations with hepatic steatosis in Mexican-origin adults	22
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	21
Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	21
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	21
Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	21
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	20
INFLUENCE OF GLYCEMIC CONTROL ON THE SEVERITY OF HEPATIC STEATOLOGY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	19
Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma	19
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	19
A practical approach to the endoscopic management of biliary strictures after liver transplantation	19
CRITICAL MEDIATORS OF INFLAMMATION-DRIVEN HEPATOCARCINOGENESIS INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	18
PLANT-DERIVED MONOTERPENE SYNERGIZES WITH SORAFENIB TO SUPPRESS DRUG-TRIGGERED HEPATOCELLULAR CARCINOMA IN ANIMALS	18
THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ADULT SUBJECTS WITH COMPENSATED LIVER CIRRHOSIS AND BACTERIAL OVERGROWTH	18
AUTOIMMUNE HEPATITIS IN LATIN AMERICA: INSIGHTS FROM THE ALLATIN COHORT	18
IMPROVEMENT OF CARDIOVASCULAR RISK ASSESSMENT ON A COHORT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)	18
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma	17
P-106 DIAGNOSTIC ACCURACY OF SHEAR-WAVE ELASTOGRAPHY IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE, A SINGLE CENTER REPORT	17
P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS	17
P-40 ASSOCIATION BETWEEN LIVER STIFFNESS MEASUREMENTS USING MR ELASTOGRAPHY AND PORTOSYSTEMIC SHUNTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE	17
P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION	17
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045	17
The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis	16
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients	16
TSH and its Correlation in the Development of Fibrosis in Patients with Hypothyroidism in a Tertiary Care Hospital	16
Ceftriaxone versus cefotaxime in the treatment of spontaneous bacterial peritonitis	16
The Hepatic Effect of Sub-chronic Chronic Cadmium Exposure.	16
Epidemiology and natural history of chronic Hepatitis B in the Canadian province of Alberta from 2012 to 2021: A population-based study	16
DILI and Dress syndrome secondary to treatment with DoTbal, in a patient with tuberculosis at the rural hospital from Papantla – IMSS Bienestar	16
Liver Injury Induced by Peumus boldus with Fatal Outcome. Case Report	16
Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis	15
Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis	15
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis	15
OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY	15
HEPATOCELLULAR CARCINOMA IN VERACRUZ: A SURVEILLANCE COMPARISON BETWEEN TREATMENTS	15
Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model	14
PORTA VEIN THROMBOSIS (PVT) IN CIRRHOTIC PATIENTS PRE AND DURING THE PANDEMIC BY SARS-COV2	14
Autoimmune hepatitis with superimposition of primary sclerosing cholangitis on non-specific chronic ulcerative colitis	14
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project	14
An exploratory analysis of patient factors influencing acceptance of extended criteria liver grafts	14
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease	13
Trajectories of patients relisted for liver transplantation	13
PROFILE OF PRO AND ANTI-INFLAMMATORY CYTOKINES IN PATIENTS WITH CHRONIC LIVER DISEASE IN THE COMPENSATION, INFLAMMATION AND IMMUNOSUPPRESSION PHASES	13
P-2 DE NOVO LIPOGENESIS MARKERS ARE INVOLVED IN METABOLIC ASSOCIATED FATTY LIVER DISEASE PROGRESSION IN BTBR OB/OB MICE	13
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	13
P-13 PREVALENCE, CHARACTERIZATION, AND SURVIVAL OF ACUTE ON CHRONIC LIVER FAILURE IN A LATIN AMERICAN COHORT: A MULTICENTER STUDY	13
P-15 MMP-2 AND MMP-9 LEVELS IN ALCOHOLIC LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC HEPATITIS C	13
HGF/c-Met regulates p22phox subunit of the NADPH oxidase complex in primary mouse hepatocytes by transcriptional and post-translational mechanisms	13
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection	13

P- 26 EFFECT OF PROTEIN X OF THE HEPATITIS B VIRUS AND HEXACHLOROBENZENE ON LIVER CELL GROWTH DYSREGULATION	12
Detection of Hepatitis C and risk factors in the general population of the Centro Médico Nacional La Raza	12
Treatment with nucleoside and nucleotide analogues in patients with chronic hepatitis B virus infection	12
P-123 HEPATOCELLULAR CARCINOMA SURVIVAL: EXPERIENCE OF THE MULTIDISCIPLINARY COMMITTEE AT HOSPITAL ESPECIALIDADES EUGENIO ESPEJO IN QUITO – ECUADOR	12
Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy	12
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA	12
CLINICAL RESULTS IN PATIENTS WITH GASTROESOPHAGEAL VARICEAL BLEEDING IN THE ICU: ANALYSIS OF 85 CASES IN A TERTIARY CARE CENTRE	11
DRUG-INDUCED DUCTOPENIA IN THE SPANISH AND LATINDILI REGISTRIES	11
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	11
PROGNOSTIC VALUE OF AST/ALT AND GGT/ALP RATIOS IN PATIENTS WITH CHOLANGIOCARCINOMA	11
LIPOUNITS: A NOVEL UNIT OF MEASUREMENT TO COMMUNICATE THE IMPACT OF DAILY HABITS ON LIVER FAT IN PATIENTS WITH MASLD	11
INCIDENCE AND PREDICTORS OF POST-TRANSPLANT MALIGNANCY IN LIVER TRANSPLANT RECIPIENTS: A SINGLE-CENTRE COHORT STUDY	11
HEPATITIS C SCREENING AND GENDER DISPARITIES IN POSITIVITY RATES IN ARGENTINA	11
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease	11
NURSING CARE STRATEGIES FOR INDIVIDUALS WITH VIRAL HEPATITIS IN THE CONTEXT OF PRIMARY HEALTH CARE	11
IMPACT OF REFRACTORY ASCITES ON THE SURVIVAL OF PATIENTS WITH CIRRHOSIS	10
Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023	10
IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico	10
Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease	10
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy	10
P-4 RISK OF HCC IN SOUTH AMERICANS ASSOCIATED WITH TLL1 VARIANT SINGLE NUCLEOTIDE POLYMORPHISM	10
DETERMINATION OF LEUKOCYTE PROFILE IN CHRONIC ALCOHOL CONSUMPTION	10
Clues to decipher the origin of severe acute hepatitis in children: a new enigma during the COVID-19 pandemic	10
Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma	10
P- 18 ANASTROZOLE MAY NOT BE ASSOCIATED FATTY LIVER DISEASE AND HEPATIC FIBROSIS IN WOMEN WITH BREAST CANCER	10
Evaluation of the MELNa AGIB Scale to Predict Mortality in Patients with Cirrhosis and Variceal Hemorrhage.	10
P- 107 EPIDEMIOLOGY, CLINICAL AND TISSUE CHARACTERISTICS OF A LARGE COHORT OF NAFLD/NASH FROM SOUTH AMERICA	10
Jejunal lymphoma of large cell high grade B monomorphic in a patient with hepatic transplant	10
MRI Imaging and Machine Learning Based Radiomics for Detection of Mixed HCC and CCA Tumors	9
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany	9
Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico	9
PROGNOSTIC ABILITY OF DIFFERENT SCORING SYSTEMS TO PREDICT VERY EARLY MORTALITY IN PATIENTS WITH CIRRHOSIS AND ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)	9
P-41 MICRORNAs FROM EVs AS POTENTIAL LIVER FIBROSIS NON-INVASIVE BIOMARKERS IN CHRONIC HEPATITIS C	9
Evaluation of the early response to empirical treatment and its association with cultures in patients with spontaneous bacterial peritonitis (SBP)	9
NON-INVASIVE ASSESSMENT OF STEATOHEPATITIS AND LIVER FIBROSIS IN THE POPULATION AT RISK FOR METABOLIC STEATOTIC LIVER DISEASE	9
Hepatic histologic findings in a murine model of diet induced-steatotic liver disease and acute alcohol intake	9
Role of tamsulosin in recovery from thioacetamide-induced subchronic liver damage in a Wistar rat model	9
FUELING THE FIRE: INFECTIONS TRIGGER AND MALNUTRITION DRIVES SEVERE ACLF IN CIRRHOSIS	9
Involvement of the Hedgehog signaling pathway in liver diseases	8
P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MA	8
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK	8
Differential effect of the allele G ADRB2 (rs1042714) and allele C ADRB3 (rs4994) and its association with metabolic-associated steatotic liver disease (MASLD) risk factors in Mexican population.	8
Serum Immunoglobulin M levels and neutrophil/lymphocyte index as predictors of treatment response in patients with primary biliary cholangitis	8
Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis	8
Stroop test, Quickstroop, and the 1-min animal naming test for minimal hepatic encephalopathy diagnosis: A multicenter study in Mexico	8
Editorial board	8
P-44 LONG-TERM SURVIVAL IN PATIENTS WITH LIVER TRANSPLANTATION	8
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease	8
MAFLD vs. MASLD: Consensus is unlike evidence!	8
O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA	8
EDITORIAL BOARD	8
Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis	7
Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis	7
Endohepatology: current status and perspectives	7
EDITORIAL BOARD	7
Different measures of sodium intake and the risk of metabolic dysfunction-associated steatotic liver disease: Evidence from the UK Biobank	7
Comment on “Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease”	7
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	7
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH	7
Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina	7
EDITORIAL BOARD	7
Validation of the Hepamet fibrosis score in a multi-ethnic Asian population	7
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation	7
Demographic and clinical characteristics of MASLD and Met-ALD patients: Insights from NHANES 2017–2020	7
P-14 SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS	7
Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis	7
EDITORIAL BOARD	7
Radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis	7
Regulation of TGF-β1, 2, and 3 and IL-10 at systemic level in chronic liver disease	7
Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients	7
Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting	7
WHAT IS THE PROGNOSTIC VALUE OF A BLOOD TEST COUNT IN PATIENTS WITH ALCOHOLIC HEPATITIS?	6
LONG-TERM ALBUMIN THERAPY MAY IMPROVE SURVIVAL IN CIRRHOSIS WITH ASCITES: A SYSTEMATIC REVIEW AND META-ANALYSIS	6
HEPATOCELLULAR CARCINOMA: CLINICAL AND EPIDEMIOLOGICAL FEATURES IN VERACRUZ	6
Metabolic dysfunction: The silenced connection with fatty liver disease	6
Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD	6
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3	6
Risk factors for sarcopenia in cirrhotic patients under evaluation for liver transplantation.	6
P-121 SEPTIC SHOCK IN LIVER CIRRHOSIS: A COHORT STUDY OF A UNIVERSITY HOSPITAL IN CHILE	6
CLINICAL CHARACTERIZATION OF HCC IN A SILENT REGION: REAL-WORLD DATA FROM A PROSPECTIVE COHORT IN CENTRAL AMERICA	6

O-11 THE PUBLIC HEALTH POLICIES REDUCE THE LONG-TERM BURDEN OF ALCOHOL-ASSOCIATED LIVER DISEASE WORLDWIDE: DEVELOPMENT OF A PREPAREDNESS INDEX	6
Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”	6
P-75 INFLUENCE OF THE ARTERIAL HEPATIC FLOW IN ELASTOGRAPHY (2D SHEARWAVE) LIVER VALUES	6
From NAFLD to MASLD: Promise and pitfalls of a new definition	6
P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT	6
Editorial board	6
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination	6
NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN THE POPULATION WITH TYPE 2 DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	6
Autoimmune hemolytic anemia as a paraneoplastic syndrome in hepatocarcinoma, case report	6
Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis	6
OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION	6
Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review	6
Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.	6
Clinical spectrum and long-term outcomes of non-cirrhotic portal venous system thrombosis in Hispanic population	6
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.	5
Sarcopenia in patients with liver cirrhosis according to hepatic functional reserve	5
P-7 EPIDEMIOLOGY OF AUTOIMMUNE HEPATITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT	5
Daytime napping and risk of liver cancer: A large population-based prospective cohort study	5
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria	5
One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection	5
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2	5
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS	5
Diethylnitrosamine and 2-acetylaminofluorene chronic administration leads to biochemical and histologic changes related to hepatocellular carcinoma in Wistar rats	5
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for	5
Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis	5
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease	5
P-77 TRIPLE THERAPY FOR DIFFICULT-TO-TREAT PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS	5
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease	5
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.)	5
ARTIFICIAL INTELLIGENCE IN PREDICTING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE: DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL IN 306 PA	5
IMPORTANCE OF P450 POLYMORPHISM IN THE DEVELOPMENT OF DILI/HILI: HISTOLOGICAL AND BIOCHEMICAL FINDINGS	5
Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: a propensity-score matched-cohort study	5
CORRELATION BETWEEN SARCOPENIA AND HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS	5
Hepatocellular carcinoma and upper gastrointestinal bleeding	5
P- 54 HEPATITIS C MICROELIMINATION IN FORMER DRUG USERS	5
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME	5
Short-term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l-ornithine, l-aspartate	5
Hepatitis C virus NS5A and core proteins regulate epithelial-mesenchymal transition biomarkers in hepatoma cells	5
The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia	5
ELIMINATION OF HEPATITIS C AMONG HEMODIALYSIS PATIENTS IN ALAGOAS, BRAZIL	5
Management of hepatocellular carcinoma recurrence after liver transplantation	5
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients	5
Colorimetric test for early diagnosis of spontaneous bacterial peritonitis.	4
EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil	4
CLINICAL, BIOCHEMICAL, AND IMAGE CHARACTERISTICS IN PATIENTS WITH A DIAGNOSIS OF AMEBIC AND BACTERIAL LIVER ABSCESS.	4
O-37 AMOXICILLIN-CLAVULANATE INDUCED LIVER INJURY: TEN YEARS EXPERIENCE FROM LATINDILI REGISTRY.	4
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure	4
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.	4
Ethanol with thioacetamide murine model of alcoholic liver disease identifies hepatic pathways as targets for the human disease	4
Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts	4
Portal cholangiopathy secondary to cavernomatous transformation of the portal vein. Case report	4
A multinational survey of physician knowledge about management of chronic hepatitis C	4
O-2 CHARACTERIZATION OF SERUM LEVELS OF BILE ACIDS, EXTRACELLULAR VESICLES AND ITS CARGO IN ALCOHOL-ASSOCIATED LIVER DISEASE	4
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis	4
P-121 CORRELATION BETWEEN HEPATOPULMONARY SYNDROME AND OXYGEN SATURATION PULSE OXIMETRY IN CIRRHOTIC PATIENTS	4
P- 73 ULTRASOUND VISUALIZATION OF THE LIVER	4
Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value	4
P- 39 N-ACETYL CYSTEINE ATTENUATES ALTERATIONS GENERATED IN EXPERIMENTAL LIVER STEATOSIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION PLUS A HYPERCALORIC DIET	4
Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire	4
MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway	4
EDITORIAL BOARD	4
Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)	4
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma	4
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY	4
Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018	4
Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?	4
O-11 ENHANCEMENT OF F4/80+CD11B-CD206+ KUPFFER CELLS IN LIVER TISSUE: EFFECT OF MARESIN-1 AS HEPATOPROTECTIVE AGENT	4
O-20 EFFECTS OF ISOCALORIC AND NEGATIVE CALORIE BALANCE EXERCISE ON SERUM LEVELS OF INSULIN-LIKE GROWTH FACTOR TYPE 1 IN SUBJECTS WITH INITIAL AND ADVANCED FATTY LIVER	3
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	3
P- 39 CLINICAL SIGNIFICANCE OF GRADE 1 HEPATIC ENCEPHALOPATHY IN PATIENTS HOSPITALIZED FOR COMPLICATIONS OF CIRRHOSIS	3
An Acknowledgement	3
Response to: MAFLD treatment: emphasizing the concept of “homology of medicine and food”	3
“Hepatocellular carcinoma surveillance: Current challenges in Latin America”	3
Liver fibrosis: More than meets the eye	3
P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.	3
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States	3
Sarcopenia as a predictor of risk of minimal hepatic encephalopathy in patients with liver cirrhosis	3
PRIMARY BILIARY CHOLANGITIS AT A TERTIARY CARE HOSPITAL	3
P-85 IMPACT OF TECHNICAL NOTE No 32/2021 ON THE RATE OF LIVER TRANSPLANTS FOR REFRACTORY ASCITIS IN A TERTIARY HOSPITAL	3
P- 44 HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS IN A PARAGUAYAN LIVER REFERENCE CENTER: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS	3
Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018–2024)	3
Non-alcoholic fatty liver disease, in contrast to alcoholic liver disease, is associated with lower socio-economic status: results from a German referral center	3
Correlation of Cardiovascular Risk Score with Alterations in Carotid Intima-Media Thickness in Patients with MASLD	3
Semaglutide for the treatment of post transplantation diabetes mellitus in patients following liver transplantation is safe and effective	3
Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients	3
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?	3
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C	3
P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLICAL HOSPITAL IN CHILE FROM 2015 TO 2022.	3
P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS	3
P-49 CONCENTRATION OF IL-12 AND CXCL-10 IN CHRONIC LIVER DISEASES	3
MORTALITY TRENDS AND RISK FACTORS IN ALCOHOL-ASSOCIATED HEPATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	3
O-1 ECONOMIC IMPACT OF LONG-TERM ALBUMIN INFUSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND UNCOMPLICATED ASCITES FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES	3
Impact of bilirubin molecular species on mortality in patients with acute on chronic liver failure (ACLF).	3
P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS	3
Evaluation of the hypolipidemic effect of cinnamon essential oil in a model of acute damage induced by triton WR-1339	3